Skip to main content

Allogene Jumps, Compugen Plunges Following Release Of Cancer Meeting Abstracts

Jefferies analyst Biren Amin raised his price target on Allogene Therapeutics to $45 from $37, while keeping a Buy rating on the shares.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.